NCT05404555

Brief Summary

For a long time, the right ventricle has been the "forgotten chamber", but with the deepening of people's understanding of the disease, right ventricular dysfunction has become an important factor to evaluate the disease progression and late prognosis of patients with AMI. Right ventricular myocardial strain derived from two-dimensional speckle tracking echocardiography is a new method for early evaluation of regional and global right ventricular systolic function, and its repeatability is much higher than that of LVEF. Acute inferior myocardial infarction is often caused by occlusion of the proximal middle segment of the right coronary artery. Many studies have confirmed that RVMS is an independent predictor of poor prognosis in patients with AIMI. However, 60% of the right ventricular systolic function is contributed by the left ventricle and interventricular septum, and the left anterior descending branch and the left circumflex branch are the main sources of blood supply to the left ventricle and interventricular septum, so in theory, non-RCA occlusion can also lead to varying degrees of right ventricular dysfunction. However, there are few studies on the role of RVMS in predicting the prognosis of AMI patients caused by non-RCA occlusion. Therefore, the purpose of this study is to prospectively study the value of dynamic changes of RVMS in predicting the prognosis of patients with acute myocardial infarction with different infarct-related vessels, in order to provide more clinical reference information for the diagnosis and treatment of AMI.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2021

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

May 31, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

June 3, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2024

Completed
Last Updated

June 24, 2022

Status Verified

March 1, 2022

Enrollment Period

2.7 years

First QC Date

May 31, 2022

Last Update Submit

June 20, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Major Adverse Cardiovascular Events

    Nonfatal stroke, nonfatal myocardial infarction, target vessel requiring revascularization, death

    2 years

Study Arms (2)

acute myocardia infarction patients with right coronary artery occlusion

Other: two-dimensional speckle tracking echocardiography

acute myocardia infarction patients with non-right coronary artery occlusion

Other: two-dimensional speckle tracking echocardiography

Interventions

Two-dimensional speckle tracking echocardiography is used to assess cardiac function in all enrolled patients

acute myocardia infarction patients with non-right coronary artery occlusionacute myocardia infarction patients with right coronary artery occlusion

Eligibility Criteria

Age35 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients with acute myocardial infarction undergoing primary percutaneous coronary intervention are included.

You may qualify if:

  • Males and females were between 35 and 85 years old;
  • coronary artery disease underwent emergency PCI for NSTEMI or primary PCI for STEMI;
  • coronary artery type was right coronary dominance;
  • regular follow-up for 2 year.

You may not qualify if:

  • Patients who cannot complete 2D speckle tracking imaging;
  • patients with severe valvular disease, cardiomyopathy, or congenital heart disease; severe liver and kidney insufficiency or chronic respiratory disease;
  • previous PCI or CABG;
  • coronary artery type: Left crown dominance.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China

RECRUITING

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 31, 2022

First Posted

June 3, 2022

Study Start

October 1, 2021

Primary Completion

May 30, 2024

Study Completion

October 30, 2024

Last Updated

June 24, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share

Locations